Tech Session IV: Nanomedicine and Nanoscale Delivery (Focus: Nano)
TGX-1214 - A Nanoemulsion Formulation of a Novel Taxoid for Treating Pancreatic Adenocarcinoma
Wednesday, July 16, 2025
3:16 PM – 3:27 PM EDT
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. In 2024, 66,440 cases of pancreatic cancer were diagnosed in the U.S., with over 51,750 deaths. The poor prognosis of unresected pancreatic cancer (PC) is compounded by multi-drug resistance and severe side effects of existing chemotherapy, highlighting the urgent need for improved treatments. To address these challenges, we developed and evaluated an oil-in-water nanoemulsion containing the next-generation taxoid DHA-SBT-1214 (TGX-1214) for localized delivery and antitumor efficacy.
Learning Objectives:
At the completion of this activity, participants will know
Learn the in vitro and in vivo evaluation techniques
Gain insight into the potential advantages
Understand the role of advanced imaging techniques
